Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., is engaged in providing custom R&D and production services for small molecule drug intermediates and a small amount of raw materials for global innovative pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Business Overview - The main products of the company include fluorinated CDMO services and non-fluorinated CDMO services [2]. - As of the 2024 annual report, overseas revenue accounts for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. - The company has a project for producing high-end pharmaceutical products, including intermediates for Semaglutide oral formulations [2][3]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 348 million yuan, representing a year-on-year growth of 32.98%, and a net profit attributable to shareholders of 71.76 million yuan, up 123.61% year-on-year [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Market Activity - On September 26, the company's stock price fell by 2.02%, with a trading volume of 64.12 million yuan and a turnover rate of 3.17%, bringing the total market capitalization to 4.272 billion yuan [1]. - The stock has shown no significant trend in major capital inflows, with a net outflow of 8.2 million yuan on the day [5][6]. Technical Analysis - The average trading cost of the stock is 39.14 yuan, with recent accumulation activity noted, although the strength of this accumulation is weak [7]. - The stock price is approaching a resistance level of 36.40 yuan, indicating potential for a pullback unless this level is broken [7].

（一）启鹭投资 1、减持股份来源：首次公开发行前持有的公司股份（含该等股份上市后资本公 积金转增股本取得的股份）。 证券代码：301509 证券简称：金凯生科 公告编号：2025-036 金凯（辽宁）生命科技股份有限公司 关于股东减持股份计划期间届满暨减持结果的公告 股东启鹭（厦门）股权投资合伙企业（有限合伙）、青岛青松创业投资集团 有限公司－青岛松凯创业投资企业（有限合伙）保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 金凯（辽宁）生命科技股份有限公司（以下简称"公司"）于近日分别收到股东 启鹭（厦门）股权投资合伙企业（有限合伙）（以下简称"启鹭投资"）、青岛青松 创业投资集团有限公司－青岛松凯创业投资企业（有限合伙）（以下简称"青松投 资"）提交的《关于减持金凯（辽宁）生命科技股份有限公司股份计划期间届满暨减 持结果告知函》，截至本报告披露日，前述股东本次减持计划期限届满。现将有关情 况公告如下： 一、股东减持情况 2、股东减持股份情况 | 股东名称 | 减持方式 | | 减持期间 | 减持均价（元 | ...

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., is engaged in providing custom research and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Business Overview - The main products of the company include fluorinated CDMO services and non-fluorinated CDMO services [2]. - As of the 2024 annual report, overseas revenue accounted for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. - The company has a project for the production of high-end pharmaceutical products, including intermediates for Semaglutide oral formulations [2][3]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 348 million yuan, a year-on-year increase of 32.98%, and a net profit attributable to the parent company of 71.76 million yuan, a year-on-year increase of 123.61% [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Market Activity - On September 25, the company's stock price increased by 0.08%, with a trading volume of 84.12 million yuan and a turnover rate of 4.07%, bringing the total market capitalization to 4.36 billion yuan [1]. - The main net inflow of funds today was 6.39 million yuan, with no significant trend in the main force's position [5][6]. Technical Analysis - The average trading cost of the stock is 39.25 yuan, with recent rapid outflows of chips, suggesting a potential recommendation for portfolio adjustment [7].

Core Viewpoint - The company JinKai Life Science has shown a positive market performance with a 1.46% increase in stock price, reaching a market capitalization of 4.357 billion yuan, while its main business focuses on providing custom R&D and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies [1][8]. Business Overview - The company's main business involves providing custom R&D and production services for small molecule drug intermediates and a limited amount of raw materials for global innovative pharmaceutical companies [2][8]. - JinKai's primary products include fluorinated CDMO services and non-fluorinated CDMO services [2]. - The company has a significant focus on Alzheimer's-related intermediates and has established capabilities in fluorination processes [3][4]. Financial Performance - For the first half of 2025, JinKai achieved a revenue of 348 million yuan, representing a year-on-year growth of 32.98%, and a net profit attributable to shareholders of 71.76 million yuan, which is a 123.61% increase compared to the previous year [8]. - The company's overseas revenue accounted for 61.18% of total revenue, benefiting from the depreciation of the Chinese yuan [4]. Market Activity - The stock has experienced a net outflow of 2.1341 million yuan from major investors today, indicating a trend of reduced holdings over the past three days [5][6]. - The average trading cost of the stock is 39.38 yuan, with the current price approaching a resistance level of 36.40 yuan, suggesting potential for upward movement if this level is surpassed [7]. Shareholder Information - As of September 19, the number of shareholders in JinKai decreased by 3.65% to 14,300, with an average of 3,968 circulating shares per person, reflecting a slight increase of 3.78% [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Institutional Holdings - As of June 30, 2025, two major funds exited the top ten circulating shareholders list, indicating potential shifts in institutional interest [10].

Company Overview - Jinkai (Liaoning) Life Science Technology Co., Ltd. is located in Fuxin City, Liaoning Province, and was established on June 8, 2009. The company went public on August 3, 2023. Its main business involves providing small molecule CDMO services to global clients in the life sciences sector, assisting pharmaceutical companies with new drug development projects by offering custom development and production services for small molecule drug intermediates and a limited amount of active pharmaceutical ingredients [2]. Financial Performance - For the period from January to June 2025, Jinkai Life Science achieved operating revenue of 348 million yuan, representing a year-on-year growth of 32.98%. The net profit attributable to the parent company was 71.76 million yuan, showing a significant increase of 123.61% compared to the previous year [2]. Shareholder Information - As of September 19, 2025, the number of shareholders in Jinkai Life Science was 14,300, a decrease of 3.65% from the previous period. The average circulating shares per person increased by 3.78% to 3,968 shares [2]. Financing and Trading Activity - On September 23, Jinkai Life Science's stock price fell by 2.46%, with a trading volume of 105 million yuan. The margin trading data indicated a financing purchase amount of 9.33 million yuan and a repayment of 9.64 million yuan, resulting in a net financing outflow of 308,900 yuan. The total margin balance as of September 23 was 140 million yuan, accounting for 6.91% of the circulating market value, which is above the 80th percentile level over the past year [1]. Dividend Distribution - Since its A-share listing, Jinkai Life Science has distributed a total of 117 million yuan in dividends [3]. Institutional Holdings - As of June 30, 2025, two funds, Yuanxin Yongfeng Ju You A and Yuanxin Yongfeng Xing Yuan A, have exited the list of the top ten circulating shareholders of Jinkai Life Science [3].

Group 1 - The company, Jinkai Biotechnology (301509), reported that as of September 19, 2025, the number of shareholders is 14,299 [1]

Group 1 - The core point of the article is that Jinkai Biotechnology (SZ 301509) held its 9th meeting of the 2nd Board of Directors on September 22, 2025, to discuss the adjustment of the Audit Committee members [1] - For the fiscal year 2024, Jinkai Biotechnology's revenue composition is as follows: CDMO accounts for 98.68%, trade and others account for 0.82%, and technical services account for 0.51% [1] - As of the report date, Jinkai Biotechnology has a market capitalization of 4.4 billion yuan [1]

2、本次股东会不涉及变更以往股东会已通过的决议。 证券代码：301509 证券简称：金凯生科 公告编号：2025-033 金凯（辽宁）生命科技股份有限公司 2025 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会不存在否决议案的情形； 一、会议召开和出席情况 1、召开时间： （1）现场会议时间：2025 年 9 月 22 日（星期一）下午 14：00。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2025 年 9 月 22 日的交易时间，即 9:15-9:25、9:30—11:30 和 13:00—15:00； 通过深圳证券交易所互联网系统投票的具体时间为 2025 年 9 月 22 日 9:15— 15:00。 2、召开地点：辽宁省阜新市阜蒙县伊吗图镇氟化工园区安仁路 6 号金凯（辽 宁）生命科技股份有限公司会议室。 3、召开方式：本次股东会采用现场表决与网络投票相结合的方式召开。 4、召集人：公司董事会。 5、主持人：董事长 FUMIN WANG（王富民）先生。 6、本次 ...

金凯（辽宁）生命科技股份有限公司 关于选举第二届董事会职工代表董事的公告 证券代码：301509 证券简称：金凯生科 公告编号：2025-034 2025年9月22日 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 金凯（辽宁）生命科技股份有限公司（以下简称"公司"）于2025年9月22日召 开2025年第一次临时股东会，审议通过《关于修订<公司章程>及相关议事规则的议 案》等。为保障董事会构成符合《中华人民共和国公司法》《深圳证券交易所创业 板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号—创业板上市公 司规范运作》等相关法律法规和规范性文件及《金凯（辽宁）生命科技股份有限公 司章程》的相关规定，公司于2025年9月22日召开职工代表大会，选举刘焕明先生 为公司第二届董事会职工代表董事（简历详见附件）。 刘焕明先生将与公司其他经股东会选举产生的7名董事共同组成公司第二届董 事会；任期自本次职工代表大会审议通过之日起至第二届董事会任期届满之日止。 本次职工代表董事选举产生后，公司第二届董事会中兼任高级管理人员职务的董事以 及由职工代表担任的董事， ...

证券代码：301509 证券简称：金凯生科 公告编号：2025-035 金凯（辽宁）生命科技股份有限公司 第二届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 董事会 董事会经审议：同意根据《公司章程》及有关法律法规规定，调整第二届董事会 审计委员会成员为：刘媛媛、游松、刘焕明；其中，刘媛媛担任召集人。 第二届董事会审计委员会成员任期自本次董事会审议通过之日起至公司第二届董 事会任期届满之日止。 表决结果：同意票8票、反对票0票、弃权票0票。 三、备查文件 第二届董事会第九次会议决议。 特此公告。 金凯（辽宁）生命科技股份有限公司 金凯（辽宁）生命科技股份有限公司（以下简称"公司"）第二届董事会第九次 会议于2025年9月22日下午16时30分在公司会议室以现场会议结合通讯方式召开。本 次会议通知豁免通知时间要求，并以现场送达结合通讯方式向全体董事送达。在保障 所有董事充分表达意见的情况下，本次会议采用现场结合通讯方式进行表决，会议应 到董事8人，实到董事8人，其中董事FUMIN WANG（王富民）、董事LIA ...